Drug-related side effects and adverse reactions: Difference between revisions
imported>Robert Badgett (New page: '''Drug toxicity''', also called '''adverse drug reaction''' or '''adverse drug event''', is defined as "manifestations of the adverse effects of drugs administered therapeutically or in t...) |
imported>Robert Badgett (Created a section on mechanisms by importing content that I helped write at WP) |
||
Line 1: | Line 1: | ||
'''Drug toxicity''', also called '''adverse drug reaction''' or '''adverse drug event''', is defined as "manifestations of the adverse effects of | '''Drug toxicity''', also called '''adverse drug reaction''' or '''adverse drug event''', is defined as "manifestations of the adverse effects of [[drug]]s administered therapeutically or in the course of diagnostic techniques. It does not include accidental or intentional poisoning..."<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2007/MB_cgi?mode=&term=Drug+Toxicity |title=Drug toxicity|author=National Library of Medicine |accessdate=2007-11-23 |format= |work=}}</ref> | ||
==Mechanisms== | |||
As research better explains the biochemistry of drug use, less ADRs are Type B and more are Type A. Common mechanisms are: | |||
* Abnormal pharmacokinetics due to | |||
** genetic factors | |||
** comorbid disease states | |||
* Synergistic effects between either | |||
** a drug and a disease | |||
** two drugs | |||
===Abnormal pharmacokinetics=== | |||
====Comorbid disease states==== | |||
Various diseases, especially those that cause [[renal failure|renal]] or [[liver failure|hepatic]] insufficiency, may alter drug metabolism. Resources are available that report changes in a drug's metabolism due to disease states.<ref>{{cite web |url=http://www.clinicaldruguse.com/ |title=Clinical Drug Use |accessdate=2007-09-18 |format= |work=}}</ref> | |||
====Genetic factors==== | |||
{{main|Pharmacogenetics|Pharmacogenomics}} | |||
Abnormal drug metabolism may be due to inherited factors of either Phase I oxidation or Phase II conjugation.<ref name="pmid11710893">{{cite journal |author=Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review |journal=JAMA |volume=286 |issue=18 |pages=2270–9 |year=2001 |pmid=11710893 |doi=}}</ref><ref name="pmid12571264">{{cite journal |author=Goldstein DB |title=Pharmacogenetics in the laboratory and the clinic |journal=N. Engl. J. Med. |volume=348 |issue=6 |pages=553–6 |year=2003 |pmid=12571264 |doi=10.1056/NEJMe020173}}</ref> | |||
=====Phase I reactions===== | |||
Inheriting abnormal [[allele]]s of [[cytochrome]] [[cytochrome P450|P450]]can alter drug metabolism. Tables are available to check for drug interactions due to P450 interactions.<ref>{{cite web |url=http://medicine.iupui.edu/flockhart/ |title=Drug-Interactions.com |accessdate=2007-09-18 |format= |work=}}</ref>.<ref name="pmid12571261">{{cite journal |author=Weinshilboum R |title=Inheritance and drug response |journal=N. Engl. J. Med. |volume=348 |issue=6 |pages=529–37 |year=2003 |pmid=12571261 |doi=10.1056/NEJMra020021}}</ref> | |||
Inheriting abnormal [[Cholinesterase enzyme|butyrylcholinesterase]] ([[Cholinesterase enzyme|pseudocholinesterase]]) may affect metabolism of drugs such as [[succinylcholine]]<ref name="pmid12571262">{{cite journal |author=Evans WE, McLeod HL |title=Pharmacogenomics--drug disposition, drug targets, and side effects |journal=N. Engl. J. Med. |volume=348 |issue=6 |pages=538–49 |year=2003 |pmid=12571262 |doi=10.1056/NEJMra020526}}</ref> | |||
=====Phase II reactions===== | |||
Inheriting abnormal [[acetyltransferase|N-acetyltransferase]] which conjugated some drugs to facilitate excretion may affect the metabolism of drugs such as [[isoniazid]], [[hydralazine]], and [[procainamide]].<ref name="pmid12571262"/><ref name="pmid12571261"/> | |||
Inheriting abnormal [[Thiopurine methyltransferase|thiopurine S-methyltransferase]] may affect the metabolism of the [[thiopurine]] drugs [[mercaptopurine]] and [[azathioprine]].<ref name="pmid12571261"/> | |||
====Interactions with other drugs==== | |||
{{main|Drug interaction}} | |||
The risk of drug interactions is increased with [[polypharmacy]]. | |||
=====Protein binding===== | |||
These interactions are usually transient and mild until a new steady state is achieved.<ref name="pmid12473961">{{cite journal |author=DeVane CL |title=Clinical significance of drug binding, protein binding, and binding displacement drug interactions |journal=Psychopharmacology bulletin. |volume=36 |issue=3 |pages=5–21 |year=2002 |pmid=12473961 |doi=}}</ref><ref name="pmid11907485">{{cite journal |author=Benet LZ, Hoener BA |title=Changes in plasma protein binding have little clinical relevance |journal=Clin. Pharmacol. Ther. |volume=71 |issue=3 |pages=115–21 |year=2002 |pmid=11907485 |doi=10.1067/mcp.2002.121829}}[http://gateway.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=11907485.ui OVID full text] [http://gateway.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE=image&IMAGE=00003098-200203000-00001%7cTT2&D=ovft summary table at OVID]</ref> These are mainly for drugs without much first-pass liver metabolism. The principle plasma proteins for drug binding are:<ref name="pmid12369572">{{cite journal |author=Sands CD, Chan ES, Welty TE |title=Revisiting the significance of warfarin protein-binding displacement interactions |journal=The Annals of pharmacotherapy |volume=36 |issue=10 |pages=1642–4 |year=2002 |pmid=12369572 |doi=|url=http://www.theannals.com/cgi/reprint/36/10/1642}}</ref> | |||
# albumin | |||
# α1-acid glycoprotein | |||
# lipoproteins | |||
Some drug interactions with warfarin are due to changes in protein binding.<ref name="pmid12369572"/> | |||
=====Cytochrome P450===== | |||
Patients have abnormal metabolism by [[cytochrome]] [[cytochrome P450|P450]] due to either inheriting abnormal [[allele]]s or due to drug interactions. Tables are available to check for drug interactions due to P450 interactions.<ref>{{cite web |url=http://medicine.iupui.edu/flockhart/ |title=Drug-Interactions.com |accessdate=2007-09-18 |format= |work=}}</ref>. | |||
===Synergistic effects=== | |||
An example of synergism is two drugs that both prolong the [[QT interval]]. | |||
Revision as of 04:20, 23 November 2007
Drug toxicity, also called adverse drug reaction or adverse drug event, is defined as "manifestations of the adverse effects of drugs administered therapeutically or in the course of diagnostic techniques. It does not include accidental or intentional poisoning..."[1]
Mechanisms
As research better explains the biochemistry of drug use, less ADRs are Type B and more are Type A. Common mechanisms are:
- Abnormal pharmacokinetics due to
- genetic factors
- comorbid disease states
- Synergistic effects between either
- a drug and a disease
- two drugs
Abnormal pharmacokinetics
Comorbid disease states
Various diseases, especially those that cause renal or hepatic insufficiency, may alter drug metabolism. Resources are available that report changes in a drug's metabolism due to disease states.[2]
Genetic factors
Abnormal drug metabolism may be due to inherited factors of either Phase I oxidation or Phase II conjugation.[3][4]
Phase I reactions
Inheriting abnormal alleles of cytochrome P450can alter drug metabolism. Tables are available to check for drug interactions due to P450 interactions.[5].[6]
Inheriting abnormal butyrylcholinesterase (pseudocholinesterase) may affect metabolism of drugs such as succinylcholine[7]
Phase II reactions
Inheriting abnormal N-acetyltransferase which conjugated some drugs to facilitate excretion may affect the metabolism of drugs such as isoniazid, hydralazine, and procainamide.[7][6]
Inheriting abnormal thiopurine S-methyltransferase may affect the metabolism of the thiopurine drugs mercaptopurine and azathioprine.[6]
Interactions with other drugs
The risk of drug interactions is increased with polypharmacy.
Protein binding
These interactions are usually transient and mild until a new steady state is achieved.[8][9] These are mainly for drugs without much first-pass liver metabolism. The principle plasma proteins for drug binding are:[10]
- albumin
- α1-acid glycoprotein
- lipoproteins
Some drug interactions with warfarin are due to changes in protein binding.[10]
Cytochrome P450
Patients have abnormal metabolism by cytochrome P450 due to either inheriting abnormal alleles or due to drug interactions. Tables are available to check for drug interactions due to P450 interactions.[11].
Synergistic effects
An example of synergism is two drugs that both prolong the QT interval.
References
- ↑ National Library of Medicine. Drug toxicity. Retrieved on 2007-11-23.
- ↑ Clinical Drug Use. Retrieved on 2007-09-18.
- ↑ Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001). "Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review". JAMA 286 (18): 2270–9. PMID 11710893. [e]
- ↑ Goldstein DB (2003). "Pharmacogenetics in the laboratory and the clinic". N. Engl. J. Med. 348 (6): 553–6. DOI:10.1056/NEJMe020173. PMID 12571264. Research Blogging.
- ↑ Drug-Interactions.com. Retrieved on 2007-09-18.
- ↑ 6.0 6.1 6.2 Weinshilboum R (2003). "Inheritance and drug response". N. Engl. J. Med. 348 (6): 529–37. DOI:10.1056/NEJMra020021. PMID 12571261. Research Blogging.
- ↑ 7.0 7.1 Evans WE, McLeod HL (2003). "Pharmacogenomics--drug disposition, drug targets, and side effects". N. Engl. J. Med. 348 (6): 538–49. DOI:10.1056/NEJMra020526. PMID 12571262. Research Blogging.
- ↑ DeVane CL (2002). "Clinical significance of drug binding, protein binding, and binding displacement drug interactions". Psychopharmacology bulletin. 36 (3): 5–21. PMID 12473961. [e]
- ↑ Benet LZ, Hoener BA (2002). "Changes in plasma protein binding have little clinical relevance". Clin. Pharmacol. Ther. 71 (3): 115–21. DOI:10.1067/mcp.2002.121829. PMID 11907485. Research Blogging. OVID full text summary table at OVID
- ↑ 10.0 10.1 Sands CD, Chan ES, Welty TE (2002). "Revisiting the significance of warfarin protein-binding displacement interactions". The Annals of pharmacotherapy 36 (10): 1642–4. PMID 12369572. [e]
- ↑ Drug-Interactions.com. Retrieved on 2007-09-18.